SCHEMBL26073602

SCHEMBL26073602

CC(=O)c1cc(-c2ccc(NC(=O)c3nc(NC(=O)OC(C)(C)C)cn3C)cc2)cn1C

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CYP17A1 P05093 5/20 0.43
GSK3B P49841 1/20 0.41
DYRK1A Q13627 1/20 0.41
MAP4K4 O95819 1/20 0.38
CD274 Q9NZQ7 1/20 0.38
PSMB8 P28062 1/20 0.36
NAMPT P43490 1/20 0.36
PRKDC P78527 1/20 0.36
TTK P33981 1/20 0.35
HDAC1 Q13547 3/20 0.35
HDAC3 O15379 2/20 0.35
HDAC2 Q92769 2/20 0.35
HDAC8 Q9BY41 2/20 0.35
BCL2 P10415 1/20 0.35
BECN1 Q14457 1/20 0.35
P2RY14 Q15391 1/20 0.35
MAPK14 Q16539 1/20 0.35
HDAC10 Q969S8 1/20 0.35
HDAC6 Q9UBN7 1/20 0.35
AR P10275 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL19739072 0.92 CYP17A1 (0.41) CYP17A1GSK3BDYRK1AMAP4K4CD274
SCHEMBL17230049 0.91 CYP17A1 (0.40) CYP17A1GSK3BDYRK1AMAP4K4CD274
SCHEMBL28458723 0.86 CYP17A1 (0.42) CYP17A1GSK3BDYRK1AMAP4K4CD274
SCHEMBL19739171 0.86 CYP17A1 (0.37) CYP17A1GSK3BDYRK1AMAP4K4CD274
SCHEMBL26073593 0.85 CYP17A1 (0.53) CYP17A1GSK3BDYRK1AMAP4K4CD274
SCHEMBL16710976 0.85 HDAC1 (0.39) CYP17A1GSK3BDYRK1AMAP4K4CD274
SCHEMBL16710975 0.84 CYP17A1 (0.43) CYP17A1GSK3BDYRK1AMAP4K4CD274
SCHEMBL22824846 0.84 HDAC1 (0.36) CYP17A1GSK3BDYRK1AMAP4K4CD274
SCHEMBL16710866 0.83 CYP17A1 (0.42) CYP17A1GSK3BDYRK1AMAP4K4CD274
SCHEMBL26073595 0.83 CYP17A1 (0.47) CYP17A1MAP4K4CD274PSMB8NAMPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11912700-B2 Anti-proliferative agents comprising substituted benzo[e]pyrido[1,2-a][1,4]diazepines PHEON THERAPEUTICS LTD (GB) 2024-02-27 US disclosed
US-20230302142-A1 Cytotoxic Agents Pheon Therapeutics Ltd. (GB) 2023-09-28 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230302142-A1 Cytotoxic Agents ANXA11, ANXA5, HAX1 CYP17A1 3163/4885GSK3B 233/4885DYRK1A 3726/4885
US-11912700-B2 Anti-proliferative agents comprising substituted benzo[e]pyrido[1,2-a][1,4]diazepines MKI67, CCND2, CCND1 CYP17A1 1348/4885GSK3B 827/4885DYRK1A 753/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.